Open Access Research article

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

Barry Singer1*, Daniel Bandari2, Mark Cascione3, Christopher LaGanke4, John Huddlestone5, Randy Bennett6, Fernando Dangond6 and REFORMS Study Group

Author Affiliations

1 Missouri Baptist Medical Center, St. Louis, MO, USA

2 Multiple Sclerosis Center of Southern California and Research Group, Newport Beach, CA, USA

3 Tampa Neurology Associates, South Tampa MS Center, Tampa, FL, USA

4 North Central Neurology Associates, Cullman, AL, USA

5 MultiCare Neuroscience Center of Washington, Tacoma, WA, USA

6 EMD Serono, Inc., One Technology Place, Rockland, MA, USA

For all author emails, please log on.

BMC Neurology 2012, 12:154  doi:10.1186/1471-2377-12-154

Published: 6 December 2012

Additional files

Additional file 1:

Table S1. Mean MSTSQ, ISR, and SF-MPQ during the safety-extension phase.

Format: DOCX Size: 17KB Download file

Open Data

Additional file 2:

Table S2. Adverse events reported by ≥5% of all patients during the safety-extension phase.

Format: DOCX Size: 16KB Download file

Open Data